Clinical Trials Directory

Trials / Terminated

TerminatedNCT03254160

DNS-3379 vs. Placebo in Stroke Rehabilitation

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 42-Day Treatment Study to Evaluate the Effect of DNS-3379 on Upper Extremity Motor Function Following Ischemic Stroke

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
1 (actual)
Sponsor
Dart NeuroScience, LLC · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of DNS-3379 on upper extremity motor recovery in subjects following ischemic stroke.

Conditions

Interventions

TypeNameDescription
DRUGDNS-3379DNS-3379
DRUGPlaceboPlacebo

Timeline

Start date
2017-11-13
Primary completion
2017-12-31
Completion
2017-12-31
First posted
2017-08-18
Last updated
2018-02-01

Locations

16 sites across 2 countries: Australia, New Zealand

Regulatory

Source: ClinicalTrials.gov record NCT03254160. Inclusion in this directory is not an endorsement.